10-Iodo-11H-indolo[3,2-c]quinoline-6-carboxylic Acids Are Selective Inhibitors of DYRK1A. Read more about 10-Iodo-11H-indolo[3,2-c]quinoline-6-carboxylic Acids Are Selective Inhibitors of DYRK1A.
Identification of 2,4-diamino-6,7-dimethoxyquinoline derivatives as G9a inhibitors†Electronic supplementary information (ESI) available. See DOI: 10.1039/c4md00274a. Read more about Identification of 2,4-diamino-6,7-dimethoxyquinoline derivatives as G9a inhibitors†Electronic supplementary information (ESI) available. See DOI: 10.1039/c4md00274a.
Ankyrin Repeats of ANKRA2 Recognize a PxLPxL Motif on the 3M Syndrome Protein CCDC8. Read more about Ankyrin Repeats of ANKRA2 Recognize a PxLPxL Motif on the 3M Syndrome Protein CCDC8.
K2P channel gating mechanisms revealed by structures of TREK-2 and a complex with Prozac. Read more about K2P channel gating mechanisms revealed by structures of TREK-2 and a complex with Prozac.
Discovery and characterization of GSK2801, a selective chemical probe for the bromodomains BAZ2A and BAZ2B. Read more about Discovery and characterization of GSK2801, a selective chemical probe for the bromodomains BAZ2A and BAZ2B.
Selective inhibitors of Cyclin-G associated kinase (GAK) as anti-HCV agents. Read more about Selective inhibitors of Cyclin-G associated kinase (GAK) as anti-HCV agents.
LLY-507, a Cell-Active, Potent and Selective Inhibitor of Protein Lysine Methyltransferase SMYD2. Read more about LLY-507, a Cell-Active, Potent and Selective Inhibitor of Protein Lysine Methyltransferase SMYD2.
Human RECQ1 helicase-driven DNA unwinding, annealing, and branch migration: Insights from DNA complex structures. Read more about Human RECQ1 helicase-driven DNA unwinding, annealing, and branch migration: Insights from DNA complex structures.
Structural and evolutionary divergence of cyclic nucleotide binding domains in eukaryotic pathogens: Implications for drug design. Read more about Structural and evolutionary divergence of cyclic nucleotide binding domains in eukaryotic pathogens: Implications for drug design.
Epigenetic targets and drug discovery Part 2: Histone demethylation and DNA methylation. Read more about Epigenetic targets and drug discovery Part 2: Histone demethylation and DNA methylation.
